Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Immuno-modulation and Autologous Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Multiple Sclerosis.

NCT03069170 is registered in ClinicalTrials.gov with Stem Cells Arabia as lead sponsor.

NCT NCT03069170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03069170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Immuno-modulation and Autologous Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Multiple Sclerosis.
Lead sponsor
Stem Cells Arabia
Phase
Phase 1
Overall status
Unknown status
Start date
July 31, 2016
Completion date
January 31, 2021
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis